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Abstract
Background: Type 2 diabetes is a risk factor for Alzheimer’s disease (AD), and AD brain shows impaired insulin
signalling. The role of peripheral insulin resistance on AD aetiopathogenesis in non-diabetic patients is still debated.
Here we evaluated the influence of insulin resistance on brain glucose metabolism, grey matter volume and white
matter lesions (WMLs) in non-diabetic AD subjects.
Methods: In total, 130 non-diabetic AD subjects underwent MRI and [18F]FDG PET scans with arterial cannula
insertion for radioactivity measurement. T1 Volumetric and FLAIR sequences were acquired on a 3-T MRI scanner.
These subjects also had measurement of glucose and insulin levels after a 4-h fast on the same day of the scan.
Insulin resistance was calculated by the updated homeostatic model assessment (HOMA2). For [18F]FDG analysis,
cerebral glucose metabolic rate (rCMRGlc) parametric images were generated using spectral analysis with arterial
plasma input function.
Results: In this non-diabetic AD population, HOMA2 was negatively associated with hippocampal rCMRGlc, along
with total grey matter volumes. No significant correlation was observed between HOMA2, hippocampal volume
and WMLs.
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Conclusions: In non-diabetic AD, peripheral insulin resistance is independently associated with reduced
hippocampal glucose metabolism and with lower grey matter volume, suggesting that peripheral insulin resistance
might influence AD pathology by its action on cerebral glucose metabolism and on neurodegeneration.
Keywords: Alzheimer’s disease, Insulin resistance, Magnetic resonance imaging, Positron emission tomography
imaging
Background
Alzheimer’s disease (AD) is the most common type of
dementia, affecting nearly 40 million people worldwide,
and is a major public health emergency of this century.
Neuropathologically, AD is characterised by extracellular
accumulation of amyloid-beta (Aβ) peptides, also known
as plaques, and intracellular neurofibrillary tangles
(NFT), aggregates resulting from tau protein hyperpho-
sphorylation [1].
The accumulation of these neurotoxic peptides in the
cerebral cortex ultimately leads to neuronal death and
gradual and progressive decline in cognitive function.
Several interventional trials have targeted these two
major pathological mechanisms in AD, but unfortu-
nately, these therapeutic strategies have not resulted in
successful treatment [2], although some studies are still
ongoing [3]. On the other hand, the most successful pre-
ventive strategies in AD are linked to targeting modifi-
able risk factors [4, 5]. Among them, growing evidence
indicates a close relationship between type 2 diabetes
mellitus and AD. Type 2 diabetes is a risk factor for AD
and epidemiological data show an almost doubled risk
for AD in diabetic patients, compared with non-diabetic
subjects [6].
Although the exact underlying mechanism is still un-
known, numerous studies have suggested that insulin re-
sistance is a key risk factor for AD [7, 8]. Insulin
resistance is defined as reduced tissue responsiveness to
the action of insulin. In AD, peripheral insulin resistance
is more common compared to control subjects [9]; in
the Rotterdam study, insulin resistance has been associ-
ated with an increased risk of AD at 3 years, even in the
absence of type 2 diabetes [6].
In addition to its peripheral actions, insulin plays an
important role in brain function. Neuronal insulin recep-
tor activation can induce dendritic sprouting, neuronal
stem cell activation, cell growth and repair [10, 11]. In-
sulin signalling induces the expression of the insulin-
degrading enzyme (IDE), which is involved in both insu-
lin and Aβ degradation; hyperinsulinemia might deter-
mine a competitive inhibition for IDE-dependent Aβ
degradation, leading to Aβ accumulation [12].
Insulin also seems to have neuroprotective effects by
regulating phosphorylated tau levels. Insulin resistance is
associated with elevated levels of proinflammatory cyto-
kines such as C-reactive protein and IL-6, which are
linked to Aβ deposition in the brain [13]. Moreover, in-
sulin improves brain functions such as attention, mem-
ory and cognition in humans [14–16]; indeed, the
insulin receptor is abundant in the hippocampus along
with cortex and thalamus [17], and in critical areas for
metabolic control such as the hypothalamus. Recent evi-
dence from a trial of intranasal insulin in AD subjects,
however, did not show benefit in terms of cognitive out-
comes at twelve months [18].
It has been shown that systemic insulin resistance and
hyperinsulinemia might reduce brain insulin levels
through a compensatory mechanism involving insulin
receptors’ reduction in the blood-brain barrier [19]. Fur-
thermore, insulin levels in cerebrospinal fluid (CSF) are
correlated with those in plasma, suggesting that most in-
sulin in the brain derives from circulating insulin [20].
Therefore, evidence suggests that peripheral insulin re-
sistance is associated with impaired brain insulin action,
although the mechanisms remain to be elucidated. Re-
cent evidence suggests that brain insulin resistance could
be an important trigger in the development of AD
neuropathology [8, 21]. Interestingly, recent study has
shown that there is significant improvement in cognition
in patients receiving anti-diabetic agent dulaglutide [22]
in diabetic patients suggesting the potential role of insu-
lin resistance in cognitive impairment in diabetic pa-
tients. However, the role of peripheral insulin resistance
in non-diabetic AD subjects has not been explored.
In this study, we sought to evaluate the possible asso-
ciation of peripheral insulin resistance with markers of
synaptic function and neurodegeneration, i.e. cerebral
glucose metabolic rate and MRI volume changes, as well
as cerebral small vessel disease, i.e. white matter lesion




In total, 130 AD subjects were enrolled as a part of the
Evaluating Liraglutide in Alzheimer’s Disease (ELAD)
study [23]. Inclusion and exclusion criteria are detailed
in Supplemental Table 1. All subjects had a diagnosis of
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probable AD according to National Institute on Ageing–
Alzheimer’s Association (NIA-AA) criteria or National
Institute of Neurological and Communicative Disorders
and Stroke–Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) criteria. Patients who
had diabetes mellitus were excluded.
All subjects had clinical and neuropsychological as-
sessment, including the Mini-Mental State Examination
(MMSE), Alzheimer’s Disease Assessment Scale-
Cognitive Subscale (ADAS-Cog), Clinical Dementia
Rating Sum of Boxes (CDR-SoB), Alzheimer’s Disease
Cooperative Study-Activities Of Daily Living (ADCS-
ADL), Geriatric Depression Scale (GDS), Controlled
Oral Word Association Test (COWAT), Category Flu-
ency Test (animals) and the Neuropsychiatric Inventory
(NPI). Furthermore, enrolled subjects had a brain
magnetic resonance imaging (MRI) scan and a brain
[18F]-fluorodeoxyglucose (FDG) positron emission tom-
ography (PET) with arterial input analysis. Glucose and
insulin levels were measured on plasma after a 4-h fast
on the day of the visit for the brain MRI and [18F]FDG
PET scan with arterial cannulation. The homeostatic
model assessment (HOMA) was performed to determine
insulin resistance; we used HOMA2, the updated
HOMA model [24]. This model can be used to deter-
mine insulin sensitivity (%S) and β-cell function (%β)
from paired fasting plasma glucose and specific insulin,
or C-peptide. In our study, we used insulin levels. Body
mass index was calculated as weight in kilogrammes/
height in metres squared.
MRI scans
MRI scans were acquired on a Verio, 3-T clinical MRI
system (Siemens, VB19) using a 32-channel head coil
and included a T1-weighted magnetization-prepared
rapid-acquisition gradient echo sequence (repetition
time = 2400 milliseconds [ms], echo time = 3.06ms, flip
angle of 9, inversion time = 900ms, matrix = 256 × 256)
generating 1-mm3 isotropic voxels, for co-registration
with the PET images for regional PET analysis. T2-
weighted MRI sequences were also acquired to evaluate
vascular and other structural abnormalities.
[18F]FDG PET scans
All subjects were scanned using a Siemens ECAT
EXACT HR+ scanner. Subjects were required to fast for
4 h before a bolus injection of 185 ± 8MBq of [18F]FDG.
A 60-min dynamic emission scan was acquired using a
predefined protocol. In all subjects, a radial artery was
cannulated. Continuous online sampling was performed
for 15 min and then discrete blood samples were taken
at baseline and at 5, 10, 15, 20, 30, 40, 50 and 60min for
radioactivity measurement. Haematocrit was estimated
from the baseline blood sample and plasma glucose
levels were measured in selected samples.
Analysis of [18F]FDG PET data
Absolute regional cerebral metabolic rate of glucose
consumption (rCMRGlc) parametric maps were gener-
ated with spectral analysis using an arterial input func-
tion and a lumped constant of 0.48. Parametric maps of
cerebral glucose metabolism were co-registered to the
individuals’ MRIs and spatially transformed into MNI
space using SPM8. Object maps were created by seg-
menting MRIs into grey matter, white matter and CSF.
This binarised grey matter map was convolved with the
probabilistic brain atlas to create individualised object
maps of volumes of interest, as previously described
[25]. We then sampled frontal, temporal, parietal and
occipital cortical regions. To further evaluate the influ-
ence of insulin resistance on subcortical regions and
medial temporal lobe structures, anterior cingulate, pos-
terior cingulate cortex, thalamus, striatum, hippocampus
and medial temporal lobe structures were sampled.
Analysis of hippocampal volume, grey matter volumes
and white matter lesion volumes
The hippocampal volume was calculated using FreeSur-
fer (Harvard Medical School; surfer.nmr.mgh.harvard.
edu) on T1-weighted images. Total (cortical and subcor-
tical) grey matter volumes were also calculated using
FreeSurfer on T1-weighted scans. Hyperintensity volu-
metrics, determined as white matter lesions (WMLs),
were segmented by the lesion growth algorithm [26] as
implemented in the LST toolbox version 3.0.0 (www.
statisticalmodelling.de/lst.html) for SPM. This algorithm
segments T2 hyperintense lesions using T1 and FLAIR
images based on a threshold (κ) for transformed inten-
sities set by the operator. After visual inspection of a
subset of 10 lesion maps at different κ, the threshold was
established at 0.3.
Statistical analysis
All statistical analyses were performed using Statistical
Package for the Social Sciences SPSS version 24 (SPSS
Inc., Chicago, IL, USA). The Shapiro–Wilk test was
employed to assess normality of the variables. HOMA2
was log transformed to approximate a normal distribu-
tion. For descriptive statistics, categorical variables were
presented as number of cases or percentage. 25th and
75th percentile values of HOMA2 were calculated and
groups falling in the lower (Q1) and upper (Q4) quartiles
were compared, where Q1 includes HOMA2 < 25th per-
centile and Q4 includes HOMA2 > 75th percentile. For
the comparison of two groups, two-tailed independent
Student’s t test was employed for the continuous
normally distributed variables. Otherwise, the Mann-
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Whitney U test was used. Pearson correlation coeffi-
cients was used to test the linear association between
HOMA2, cognitive measures, rCMRGlc, hippocampal,
total grey matter and WML volume. Significant associa-
tions between HOMA2 and imaging measures were
tested for quantitative relationship by multiple regres-
sion analysis. Significance was set at a p value < 0.05.
Results
The demographic characteristics of the population are
shown in Table 1. The mean age of our AD population
was 71.8 ± 7 years (age range 55–85 years). The mean
Mini-Mental State Examination scores (MMSE) were
24.1 ± 3.1, mean ADAS-Cog was 31.9 ± 9.9, with a mean
Clinical Dementia Rating scale (sum of boxes) of 3.6 ±
1.8. On average, scores on the 30-item Geriatric Depres-
sion Scale were low suggesting that these subjects were
not depressed, and one quarter of the study population
was on antidepressants. Phonetic and semantic scores
were below normative thresholds [27]. The great major-
ity of subjects (82.3%) were on treatment with acetylcho-
line esterase inhibitors.
These subjects had normal fasting mean levels of
plasma glucose, insulin and HbA1c, indicating a good
euglycemic control in this non-diabetic population. The
average BMI was 25.9 ± 4.3. The mean HOMA2 index in
our group was 1.1 ± 0.9, with HOMA %β (steady-state β
cell function as percentages of a normal reference popu-
lation) being 98.6 ± 63.5 and HOMA %S (and insulin
sensitivity as percentages of a normal reference popula-
tion) was 147.6 ± 105.1.
rCMRGlc in the different ROIs, hippocampal volumes,
WML and grey matter volumes are detailed in Table 2.
In particular, mean hippocampal rCMRGlc was 0.19 ±
0.03 μmol/g/min, total grey matter volume was 556,
401.9 ± 52,622.8 mm3, total (left and right) hippocampal
volume was 3062.2 ± 458.6 mm3 and WML volume was
6.79 ± 7.7 ml.
rCMRGlc showed significant inverse correlation with
scores on the ADAS-Cog examination in the cortical
ROIs in the frontal (Pearson’s r = −0.36 [− 0.52–0.18]
p < 0.00), temporal (Pearson’s r = − 0.45 [− 0.62–0.30]
p < 0.00), parietal (Pearson’s r = − 0.48 [− 0.62–0.34] p <
0.00) and occipital lobes (Pearson’s r = − 0.33 [− 0.49–
0.15] p = 0.01). ADAS-Cog was also negatively correlated
with hippocampal volume (Pearson’s r = − 0.30 [− 0.48–
0.10] p < 0.00).
Linear correlation between log transformed HOMA2,
rCMRGlc in the predefined cortical regions, hippocam-
pal, total grey matter and WMLs was tested with Pear-
son correlation coefficient. HOMA2 showed a significant
inverse correlation with rCMRGlc in the hippocampus
(Pearson’s r = − 0.26 [− 0.45–0.07] p < 0.02) and total
grey matter volume (Pearson’s r = − 0.23 [− 0.42–0.04]
p < 0.04). No significant correlation was observed be-
tween HOMA2 and hippocampal volume. Bias corrected
and accelerated bootstrap 95% CIs are reported in
square brackets. On multiple regression analysis models
corrected by age and gender, log transformed HOMA2
was independently associated with hippocampal
rCMRGlc (R2 = 0.19, p = 0.01) and with total grey matter
volume (R2 = 0.37, p = 0.01) (Fig. 1).
Table 1 Baseline characteristics of subjects
Age, years 71.8 ± 7.0
Gender, M/F 80/50
BMI, kg/m2 25.9 ± 4.3
Plasma glucose, mmol/L 4.9 ± 0.5
Plasma insulin, mIU/L 8.4 ± 7.3
HbA1c, mmol/mol 37.1 ± 6.6
HOMA2, mass units 1.1 ± 0.9
HOMA2%β 98.6 ± 63.5
HOMA2%S 147.6 ± 105.1
Total serum cholesterol, mmol/L 4.9 ± 1.3
LDL cholesterol, mmol/L 2.9 ± 1.0
HDL cholesterol, mmol/L 1.7 ± 0.6
Serum triglycerides, mmol/L 1.6 ± 0.8
On treatment with AchE-I (% of total) 82.9
On treatment with antidepressants (% of total) 25.5
MMSE 24.1 ± 3.1
CDR-SoB 3.6 ± 1.8
ADAS-Cog 31.9 ± 9.9
GDS 5.5 ± 4.7
ADCS—ADL 66.6 ± 9.1
COWAT average (total acceptable words) 10.2 ± 4.8 (30.1 ± 13.6)
Category fluency test (animals) 10.6 ± 5.1
NPI 9.6 ± 11.6
NPI—caregiver distress 5.0 ± 6.1
Anterior cingulate rCMRGlc, μmol/g/min 0.27 ± 0.05
Posterior cingulate rCMRGlc, μmol/g/min 0.30 ± 0.05
Frontal lobe rCMRGlc, μmol/g/min 0.31 ± 0.05
Temporal lobe rCMRGlc, μmol/g/min 0.23 ± 0.04
Parietal lobe rCMRGlc, μmol/g/min 0.26 ± 0.05
Occipital lobe rCMRGlc, μmol/g/min 0.28 ± 0.05
Medial Temporal lobe rCMRGlc, μmol/g/min 0.19 ± 0.03
Hippocampal rCMRGlc, μmol/g/min 0.19 ± 0.03
Thalamus rCMRGlc, μmol/g/min 0.25 ± 0.05
Striatum rCMRGlc, μmol/g/min 0.30 ± 0.05
Hippocampal volume, mm3 3062.2 ± 458.6
White matter lesions volume, ml 6.79 ± 7.7
Total grey matter volume, mm3 556,401.9 ± 52,622.8
Continuous data are shown as mean ± standard deviation
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To test for an effect of disease severity on the
association between HOMA2, hippocampal rCMRGlc
and total grey matter volume, we further corrected
our models by CDR scores: in these models, CDR
scores were not significant predictors of hippocampal
rCMRGlc (R2 = 0.24, p = 0.01 for the model) or of
total grey matter volume (R2 = 0.38, p = 0.01 for the
model).





Age, years 72.3 ± 5.6 71.5 ± 7.6
Gender, M/F 19/13 20/12
BMI, kg/m2 23.6 ± 3.7 27.4 ± 4.8 *
Plasma glucose, mmol/L 4.6 ± 0.5 5.2 ± 0.6 *
Plasma insulin, mIU/L 2.9 ± 0.8 17.5 ± 9.7 *
HbA1c, mmol/mol 36.9 ± 4.0 38.0 ± 5.4
HOMA2, mass units 0.37 ± 0.1 2.2 ± 1.1 *
HOMA2%β 58.5 ± 18.2 160.3 ± 99.4 *
HOMA2%S 295.9 ± 100.6 52.6 ± 16.6 *
Total serum cholesterol, mmol/L 5.1 ± 1.4 4.4 ± 0.9
LDL cholesterol, mmol/L 3.0 ± 1.0 2.3 ± 0.8 *
HDL cholesterol, mmol/L 1.9 ± 0.6 1.6 ± 0.7 *
Serum triglycerides, mmol/L 1.2 ± 0.5 1.7 ± 0.6 *
On statin treatment, % 40.6 53.1
On antihypertensive treatment, % 28.1 37.5
MMSE 23.8 ± 3.0 23.6 ± 2.7
CDR-SoB 3.6 ± 1.4 3.5 ± 1.5
ADAS-Cog 33.8 ± 12.0 32.5 ± 9.1
GDS 5.7 ± 4.2 5.4 ± 4.9
ADCS—ADL 68.7 ± 7.3 66.6 ± 8.8
COWAT average (total acceptable words) 10.8 ± 5.5 (29.8 ± 14.2) 9.6 ± 4.2 (29 ± 13.3)
Category fluency test (animals) 10.5 ± 5.0 10.8 ± 5.4
NPI 8.1 ± 9.1 11.2 ± 15.0
NPI—caregiver distress 4.3 ± 4.4 5.9 ± 9.1
On treatment with AchE-I, % 77.4 90.6
On treatment with antidepressants, % 25 21.9
Anterior cingulate rCMRGlc, μmol/g/min 0.28 ± 0.03 0.27 ± 0.04
Posterior cingulate rCMRGlc, μmol/g/min 0.30 ± 0.04 0.30 ± 0.05
Frontal lobe rCMRGlc, μmol/g/min 0.31 ± 0.03 0.30 ± 0.05
Temporal lobe rCMRGlc, μmol/g/min 0.23 ± 0.03 0.23 ± 0.03
Parietal lobe rCMRGlc, μmol/g/min 0.26 ± 0.04 0.26 ± 0.04
Occipital lobe rCMRGlc, μmol/g/min 0.28 ± 0.04 0.27 ± 0.04
Medial temporal lobe rCMRGlc, μmol/g/min 0.20 ± 0.02 0.19 ± 0.03 *
Hippocampal rCMRGlc, μmol/g/min 0.21 ± 0.02 0.19 ± 0.03 *
Thalamus rCMRGlc, μmol/g/min 0.25 ± 0.03 0.24 ± 0.05
Striatum rCMRGlc, μmol/g/min 0.31 ± 0.03 0.30 ± 0.06
Hippocampal volume, mm3 3183.0 ± 437.9 3038.9 ± 392.4
White matter lesions volume, ml 4.6 ± 4.6 6.1 ± 6.2
Total grey matter volume, mm3 563,626.3 ± 44,128.6 539,331.9 ± 44,547.8 *
* p < .05 for Q1 vs Q4 on independent sample t-test or Mann-Whitney U test
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To take into account of the atrophy, when we created
the individualised object map, we multiplied the atlas
with individual subject’s grey matter. This ensures that
we are not sampling any regions outside the grey matter.
Moreover, in order to take into account the effects of at-
rophy on FDG measures, we built a multiple regression
model to test the association between HOMA2 and hip-
pocampal rCMRGlc corrected by age and total grey mat-
ter volume. In this model, total grey matter volume was
not a significant predictor of hippocampal rCMRGlc
(R2 = 0.17, p = 0.02). When hippocampal rCMRGlc was
normalised by individual hippocampal volumes,
HOMA2 remained a significant predictor, even correct-
ing by age (R2 = 0.15, p = 0.02).
Interestingly, WML volume was not correlated with
HOMA2, but it positively correlated with serum trigly-
ceride levels. In a multiple regression model, serum tri-
glyceride levels were significant predictors of WMLs also
after correcting by age and gender (R2 = 0.22, p = 0.00)
(Supplemental Fig. 1).
To compare the subjects with a higher HOMA2 index
versus those with a lower index, we divided the popula-
tion into quartiles of HOMA2 index distribution and
compared the group in the first quartile (Q1, or below
25th percentile) with the group in the fourth quartile
(Q4, or above 75th percentile). The Q1 group was com-
posed of the subjects (n = 32) whose HOMA2 was less
than 0.54, while the Q4 group (n = 32) comprised partic-
ipants whose HOMA2 was above 1.39.
We then compared the biomarkers and cognitive mea-
sures in these two groups (Table 2). Q4 subjects showed
significantly reduced rCMRGlc in the hippocampus (p =
0.04) and in the MTL (p = 0.04) compared with Q1
subjects. Moreover, total grey matter volume was signifi-
cantly reduced in Q4 subjects compared with Q1 (p =
0.03 and p = 0.01, respectively). Hippocampal volume
and the volume of WMLs were not significantly different
between the two groups. Fasting plasma glucose levels
were 4.6 ± 0.5 mmol/L and 5.2 ± 0.6 mmol/L in the Q1
and Q4 groups, respectively (p < 0.05) and fasting plasma
insulin levels were 2.9 ± 0.8 mIU/Lin Q1 and 17.5 ± 9.7
mIU/L in Q4 (p < 0.05). Overall, the cognitive and func-
tional measures were not significantly different between
the two groups. Q4 subjects showed lower levels of LDL
and HDL cholesterol, as well as higher triglyceride levels
compared with Q1 subjects. The percentage of subjects
on statin treatment and antihypertensive treatment was
similar between the two groups. Moreover, Q4 subjects
had significantly higher BMI compared with Q1
subjects.
Discussion
In this study, we demonstrated that, in a non-diabetic
population of AD subjects, peripheral insulin resistance
measured as HOMA2 is associated with reduced cere-
bral glucose metabolism measured by [18F]FDG PET
and with reduced grey matter volume suggesting insulin
resistance has significant influence on neurodegenera-
tion even in non-diabetic AD patients. Interestingly,
small vessel disease in our population was not affected
by insulin resistance suggesting insulin resistance can
exert its effect independent of cerebral small vessel dis-
ease in non-diabetic AD population.
This is the first study in the non-diabetic AD popula-
tion to highlight the association of insulin resistance
with hypometabolism and grey matter atrophy, and
Fig. 1 Multiple linear regression between HOMA2, hippocampal rCMRGlc and total grey matter volume. a The inverse association between log
transformed HOMA2 hippocampal rCMRGlc, in a multiple regression model corrected by age and gender (R2 = 0.19, p = 0.01). Log transformed
HOMA2 was negatively associated with total grey matter volumes (R2 = 0.37, p = 0.01), in a multiple regression model corrected by age and
gender (b). rCMRGlc is expressed in μmol/g/min, total grey matter volumes are expressed in mm3
Femminella et al. Alzheimer's Research & Therapy           (2021) 13:47 Page 6 of 11
insulin resistance in our cohort was not associated with
white matter lesions. It has been suggested that periph-
eral insulin resistance might mirror central insulin re-
sistance in diabetic patients; however, not many studies
have evaluated the influence of insulin resistance in non-
diabetic AD patients. It is proposed that insulin resist-
ance might precede the development of AD in patients
predisposed to diabetes [28, 29]. While, in diabetic pa-
tients, PET studies have demonstrated that greater insu-
lin resistance is associated with an AD-like pattern of
reduced cerebral glucose metabolic rate in frontal, parie-
totemporal and cingulate regions [30], our cohort did
not include subjects with type 2 diabetes and thus the
confounding factors related to diabetes, such as systemic
diabetic complications and the effects of anti-diabetic
medications, are not present in the results of our study.
Indeed, other comorbidities of type 2 diabetes (hypergly-
caemia, inflammation, dyslipidaemia, renal failure,
hypertension) have their own complex effects on brain
function. In this study of non-diabetic subjects, the con-
clusions we draw relate to peripheral insulin resistance,
devoid of the interactions with the other diabetes co-
morbidities and white matter changes.
A study in a cohort of non-diabetic mild cognitive im-
pairment (MCI) subjects has shown an association be-
tween HOMA2-reduced performance in verbal fluency
tests [31], but the authors did not evaluate AD
biomarkers. Willette et al. evaluated AD subjects from
the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
cohort which included diabetic subjects and showed an
inverse association between HOMA2 and brain metabol-
ism [32]. To our knowledge, no other studies have evalu-
ated the association of insulin resistance with AD
biomarkers in non-diabetic patients. Thus, our results
further support the hypothesis that the action of insulin
in the brain goes beyond glycaemic control and
diabetes-related changes in the brain. Furthermore, al-
though insulin resistance increases with age and, in older
adults without dementia cortical insulin concentration is
decreased, in our population the association between in-
sulin resistance brain hypometabolism and grey matter
volume was independent of age and gender.
It is known that increased insulin signalling in the
brain might reduce Aβ accumulation; insulin has also
been reported to enhance Aβ clearance from the brain
[33]. Moreover, insulin resistance is known to be associ-
ated with increased levels of proinflammatory cytokines
such as C-reactive protein, tumour necrosis factor-
(TNF-) α, interleukin- (IL) 1, and IL-6 [13]. IL-6 and C-
reactive protein are linked to Aβ plaque deposition and
progression, and it is known that patients under chronic
nonsteroidal anti-inflammatory therapy have reduced in-
cidence of AD. Another relevant aspect is represented
by the proinflammatory role of astrocytes and microglia
surrounding Aβ plaques that are responsible for irrevers-
ible neuronal damage if chronically activated. Interest-
ingly, insulin seems to have anti-inflammatory effects
directly suppressing proinflammatory cytokines and in-
ducing anti-inflammatory mediators, as demonstrated in
both preclinical and clinical studies [34]. Nasal applica-
tion of insulin, which allows it to enter the brain more
directly than other administration routes, has clear ef-
fects on attention and memory formation. Pilot trials of
intranasal insulin in patients with AD and MCI im-
proved cognition and functional ability compared with
placebo, while cerebral [18F]FDG uptake significantly
worsened in the placebo-treated group [15]. Recently,
the long-lasting insulin, detemir, has been tested for
intranasal administration in AD and MCI, showing a
treatment effect for the memory composite outcome
compared with placebo. Like previous studies, this effect
was moderated by the APOE status [35]. However,
evidence from a recent trial of intranasal insulin in AD
subjects did not show benefit in terms of cognitive out-
comes at 12 months [18].
In our cohort, a higher insulin resistance index was as-
sociated with lower hippocampal rCMRGlc, but not with
hippocampal atrophy or cerebrovascular (small vessel)
disease, and one could argue that the mechanisms
underlying hippocampal atrophy or white matter
changes in our non-diabetic population are independent
of peripheral insulin resistance. In particular, the avail-
able evidence suggests that hippocampal atrophy is a
hallmark and probably the starting point of the patho-
genesis of AD. Deposition of tau protein, formation of
neurofibrillary tangles and accumulation of amyloid con-
tributes to hippocampal atrophy, together with damage
caused by several other factors. In our study, insulin re-
sistance was negatively associated with total grey matter
volume. It is known that diabetic patients show in-
creased brain atrophy compared with healthy controls,
but the underlying mechanisms are not well explained
and might go beyond insulin resistance. Type 2 diabetes
has been independently associated with reduced frontal
and parietal cortical thickness in the ADNI cohort [36]
and a voxel-based morphology study has demonstrated
that the grey matter volume loss attributable to type 2
diabetes involves mainly temporal lobe, parahippocam-
pus, cingulate gyrus and medial frontal regions [37]. In-
deed, studies in patients with type 2 diabetes have not
shown increased AD-like biomarkers in their CSF [38]
and no difference in CSF biomarkers has been demon-
strated between insulin resistance and non-insulin resist-
ance in cognitively healthy individuals [39]. The
cerebrovascular burden in our cohort that we measured
from WML volume was not associated with insulin re-
sistance. An association with age was found, as expected,
and interestingly an independent positive relationship
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with serum triglyceride levels, as also shown in other
elderly populations [40]. Previous studies have shown
variable associations between insulin resistance and AD-
like brain changes. In a non-diabetic, cognitively intact
cohort of post-menopausal women at risk for AD, a sig-
nificant negative relationship between HOMA-IR and
right and total hippocampal volume, overall cognitive
performance and selective tests of verbal and non-verbal
memory was demonstrated [41]. A voxel-based morph-
ometry study in middle-aged cognitively normal adults
showed that higher insulin resistance predicted less grey
matter at baseline and 4-year follow-up in medial tem-
poral lobe, prefrontal cortices, precuneus and parietal
gyri [42]. Others have reported that, in early AD, higher
insulin response to intravenous glucose tolerance test
was associated with less longitudinal decline in cognitive
performance, and less regional atrophy in the bilateral
hippocampi and cingulate cortices [43]. Interestingly, a
recent study on plasma exosomal biomarkers of insulin
resistance found a negative association between a marker
of insulin resistance and bilateral parietal-occipital junc-
tion and right middle temporal gyrus volumes in pa-
tients with early AD [44].
In asymptomatic APOE e4 carriers, insulin resistance
has been associated with higher CSF levels of tau, sug-
gesting that insulin resistance might contribute to neu-
rodegeneration [45]. In subjects with family history of
AD, higher insulin resistance has been associated with
reduced cerebral glucose metabolism [46], as well as
changes in CSF Aβ and tau and worse memory perform-
ance, especially in APOE e4 carriers [47]. Recently, it has
been shown that insulin sensitivity, together with adher-
ence to a Mediterranean-style diet, were positively asso-
ciated with MRI-based cortical thickness in middle-aged
adults [48]. In addition to these observations, WMLs,
detected as a high-intensity area in FLAIR MRI, reflect
small vessel damage in periventricular and subcortical
areas of the brain. They are associated with progression
of cognitive decline and studies in diabetes have shown
that WML severity is correlated with cognitive decline,
suggesting that insulin resistance might be the exacer-
bating factor [49]. The findings from our study suggest
that factors related to diabetes other than insulin resist-
ance might contribute to cerebrovascular pathology.
The age range for our study population is 55–85 years,
including a proportion of subjects that could be classi-
fied as early-onset Alzheimer’s disease (EOAD). We did
not see a difference between the insulin resistance in this
group compared with the older age group. Some studies
in subjects with nmEOAD without AD family history
have shown more atrophy and more prominent cortical
hypometabolism compared to LOAD [50]. Moreover,
age is known to affect IR. Indeed, in older persons, age-
related changes in body composition, mitochondrial
dysfunction, increased inflammation, oxidative stress
and modified activity of insulin sensitivity regulatory en-
zymes increase the risk of developing IR [51]. In our
study population, however, age did not seem to affect
the relationship between peripheral IR and hippocampal
glucose metabolism. Moreover, there was no significant
difference in age between subjects with low or high
HOMA2 index.
Kim et al. demonstrated an inverse association be-
tween insulin resistance and performance on verbal flu-
ency tests in non-diabetic subjects with MCI, with a
significant interaction of the APOE e4 carrier status
[31]. Data from diabetic patients suggest that higher in-
sulin resistance is associated with lower cognitive per-
formance [52], while recent longitudinal evidence
suggests that insulin resistance is an independent pre-
dictor of poor verbal fluency for 11 years follow-up [53].
Although the results of our study are not conclusive re-
garding the role of insulin resistance in non-diabetic
AD, our findings highlight the fact that insulin resistance
might be a modifiable risk factor and could be a poten-
tial therapeutic target in dementia prevention, also in
non-diabetic subjects. However, it should also be noted
that the relationship between AD pathology and insulin
resistance could be bidirectional: the protracted accumu-
lation of Aβ and tau with consequent neurodegeneration
in areas of the brain such as the hypothalamus in AD
could alter the central regulation of body energy metab-
olism and promote systemic insulin resistance [54].
In our cohort, subjects in the highest quartile of
HOMA2 presented with higher BMI, higher serum tri-
glyceride levels and lower HDL cholesterol levels. The
proportion of subjects on antihypertensive treatment
was not significantly different between subjects with low
or high HOMA2 index. IR measured by HOMA2 repre-
sents a component and an underlying factor of the meta-
bolic syndrome, together with hypertension, obesity and
dyslipidaemia. These risk factors cluster together and are
linked to increased risk of diabetes and coronary heart
disease [55]. Studies have shown that fasting hyperinsuli-
nemia/insulin resistance preceded the development of
other aspects of the metabolic syndrome including
hypertension, hypertriglyceridemia and reduced HDL.
Moreover, even after adjusting for obesity, significant re-
lationships between insulin and the other factors have
been observed [56]. Therefore, it would be difficult to
evaluate the modifying effects of single metabolic factors
on brain glucose metabolism, as they are all part of the
same cluster of metabolic alterations and are correlated
to each other.
Limitations
One of the limitations of our study is the unknown Aβ
or tau status of our subjects, thus a global amyloid/tau/
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neurodegeneration (A/T/N) classification, as suggested
by the most recent guidelines, was not possible [57].
Moreover, the data on APOE genotype are not avail-
able in this cohort. HOMA2 provides a measure of
insulin resistance derived from fasting blood glucose
and insulin levels, as well as measures of β-cell
function and insulin sensitivity, which employs a non-
linear model and constitutes the updated and recom-
mended version of the original HOMA model [58].
However, the euglycemic-hyperinsulinemic clamp
would provide a closer measure of insulin sensitivity,
but was beyond the scope of this study. Although ma-
jority of the scans were performed around mid-day
following 4 h fasting in a relatively short time window
during the day (all the scans were performed between
10 AM and 3 PM), we cannot exclude that the actual
time of the day might have some influence on glucose
and insulin levels, which are known to follow a diur-
nal pattern [59]. However, variations in secretion are
most evident when comparing early morning versus
evening measurements [60, 61]. Lastly, the cross-
sectional nature of this work does not allow for
evaluating the predictive role of insulin resistance on
AD-related biomarker change. Our findings provide
further evidence on the association between periph-
eral insulin resistance and brain glucose metabolism
and atrophy in AD, even in non-diabetic subjects. In
addition to that, the disappointing results from most
anti-amyloid therapeutic strategies in AD clearly indi-
cate that other pathways need to be explored in the
search for disease-modifying agents in AD. The
pathophysiological connections between AD and type
2 diabetes provide further evidence for novel thera-
peutic strategies.
Conclusion
In this non-diabetic AD population, insulin resistance
was negatively associated with hippocampal glucose me-
tabolism, along with total grey matter volume. This
highlights the influence of peripheral insulin resistance
on the neurodegenerative process even in non-diabetic
AD subjects. The findings from our study support the
importance of metabolic risk factors in non-diabetic AD
patients and highlight the potential role of novel thera-
peutic strategies targeting insulin resistance.
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